Figure 3: Relative use of mammalian- versus nonmammalian-based production cell lines in the manufacture of biopharmaceuticals approved over the indicated periods. | Nature Biotechnology

Figure 3: Relative use of mammalian- versus nonmammalian-based production cell lines in the manufacture of biopharmaceuticals approved over the indicated periods.

From: Biopharmaceutical benchmarks 2018

Figure 3

Each dataset is expressed as a percentage of total biopharmaceutical product approvals for the period in question.

Back to article page